BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 31809230)

  • 1. Gadolinium Deposition and Nephrogenic Systemic Fibrosis: A Radiologist's Primer.
    Mathur M; Jones JR; Weinreb JC
    Radiographics; 2020; 40(1):153-162. PubMed ID: 31809230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience.
    Lemy AA; del Marmol V; Kolivras A; High WA; Matos C; Laporte M; Nortier JL
    J Am Acad Dermatol; 2010 Sep; 63(3):389-99. PubMed ID: 20619488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of nephrogenic systemic fibrosis.
    Daftari Besheli L; Aran S; Shaqdan K; Kay J; Abujudeh H
    Clin Radiol; 2014 Jul; 69(7):661-8. PubMed ID: 24582176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure.
    Bernstein EJ; Schmidt-Lauber C; Kay J
    Best Pract Res Clin Rheumatol; 2012 Aug; 26(4):489-503. PubMed ID: 23040363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GBCAs and Risk for Nephrogenic Systemic Fibrosis: A Literature Review.
    Beam AS; Moore KG; Gillis SN; Ford KF; Gray T; Steinwinder AH; Graham A
    Radiol Technol; 2017 Jul; 88(6):583-589. PubMed ID: 28900045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gadolinium-based contrast agents in children.
    Rozenfeld MN; Podberesky DJ
    Pediatr Radiol; 2018 Aug; 48(9):1188-1196. PubMed ID: 30078039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrogenic systemic fibrosis and gadolinium-based contrast agents.
    Abu-Alfa AK
    Adv Chronic Kidney Dis; 2011 May; 18(3):188-98. PubMed ID: 21531325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nephrogenic systemic fibrosis: a severe complication of use to gadolinium in patients with kidney failure].
    Mundim JS; Lorena Sde C; Abensur H; Elias RM; Moysés RM; Castro MC; Romão Júnior JE
    Rev Assoc Med Bras (1992); 2009; 55(2):220-5. PubMed ID: 19488662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
    Weinreb JC; Abu-Alfa AK
    J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis.
    Zhang B; Liang L; Chen W; Liang C; Zhang S
    PLoS One; 2015; 10(6):e0129720. PubMed ID: 26076348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration.
    Yang L; Krefting I; Gorovets A; Marzella L; Kaiser J; Boucher R; Rieves D
    Radiology; 2012 Oct; 265(1):248-53. PubMed ID: 22923714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis.
    Agarwal R; Brunelli SM; Williams K; Mitchell MD; Feldman HI; Umscheid CA
    Nephrol Dial Transplant; 2009 Mar; 24(3):856-63. PubMed ID: 18952698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadolinium tissue deposition in the periodontal ligament of mice with reduced renal function exposed to Gd-based contrast agents.
    Delfino R; Biasotto M; Candido R; Altissimo M; Stebel M; Salomè M; van Elteren JT; Vogel Mikuš K; Zennaro C; Šala M; Addobbati R; Tromba G; Pascolo L
    Toxicol Lett; 2019 Feb; 301():157-167. PubMed ID: 30476537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents.
    Penfield JG
    Pediatr Nephrol; 2008 Dec; 23(12):2121-9. PubMed ID: 18543004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrogenic systemic fibrosis: A survey of the use of gadolinium-based contrast agents in Ghana.
    Piersson AD; Gorleku PN
    Radiography (Lond); 2017 Nov; 23(4):e108-e113. PubMed ID: 28965904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrogenic systemic fibrosis.
    Weinreb JC; Kuo PH
    Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the Patient with Reported Gadolinium-Associated Illness.
    Lyapustina T; Goldfine C; Rhyee S; Babu KM; Griswold MK
    J Med Toxicol; 2019 Jan; 15(1):36-44. PubMed ID: 30499040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States.
    Thomsen HS
    Radiol Clin North Am; 2009 Sep; 47(5):871-5, vii. PubMed ID: 19744601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gadolinium-Induced Fibrosis.
    Todd DJ; Kay J
    Annu Rev Med; 2016; 67():273-91. PubMed ID: 26768242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents.
    Pietsch H; Lengsfeld P; Steger-Hartmann T; Löwe A; Frenzel T; Hütter J; Sieber MA
    Invest Radiol; 2009 Apr; 44(4):226-33. PubMed ID: 19252439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.